Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders and an amendment to its charter. Stockholders approved a Certificate of Amendment increasing authorized capital stock from 125,000,000 to 245,000,000 shares and authorized common stock from 120,000,000 to 240,000,000 shares. The additional common stock has the same rights as existing common shares, and the amendment became effective upon filing with the Delaware Secretary of State on June 9, 2026. Stockholders also elected directors and approved other meeting proposals based on the votes disclosed.
Voyager Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, an investigational tau silencing gene therapy for Alzheimer’s disease. This clearance allows the company to start human testing.
The company plans a multi-site, open-label, dose-escalation trial beginning dosing in the second half of 2026. VY1706 will be given once by intravenous infusion to adults with early Alzheimer’s who show tau pathology on PET imaging. The study will enroll up to 18 patients across three dose cohorts, with the highest dose not exceeding 5 x 1013 vector genomes per kilogram.
The primary goal is to evaluate safety and tolerability. Secondary measures will look at effects on tau biology, including changes in cerebrospinal fluid tau biomarkers and tau pathology assessed by tau PET imaging. The company also highlights typical development risks and uncertainties that could affect timing, results, and future plans.
Voyager Therapeutics, Inc. Principal Accounting Officer Amy Quinlan filed an initial statement of beneficial ownership. She directly holds 36,749 shares of common stock and two stock option awards covering 28,500 shares at $3.68 per share and 50,000 shares at $5.28 per share.
The options, issued under the company’s 2015 and 2025 stock plans, vest over four years on specified schedules, with each restricted stock unit representing one share of common stock upon vesting.
VYGR affiliate filed a Form 144 to sell 25,000 shares of Common Stock. The notice lists two restricted stock vesting entries of 19,000 shares (10/01/2025) and 6,000 shares (02/21/2026) as the securities to be sold. A prior disposition of 4,668 shares was reported on 02/24/2026.
The filing names a broker-dealer and shows a reported cash figure of $96,940.70 on the cover line. Timing and sale mechanics are those typical of a Form 144 notice for affiliate resale.
Voyager Therapeutics, Inc. Schedule 13G/A amendment shows that EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman each report 0 shares and 0% beneficial ownership of Voyager common stock (CUSIP 92915B106) in this filing. The filing states the reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest.
Voyager Therapeutics disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,500,000 shares of common stock, representing 5.87% of the class. The filing states shared voting and dispositive power over those shares.
The filing explains Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the reported shares.
Voyager Therapeutics (VYGR) notice of proposed sale of 9,406 shares of common stock under Section 144, with the transaction dated 05/15/2026. The filing notes an option granted on 02/06/2026 and lists 60,421,287 shares outstanding as of 05/15/2026 as a context figure. The record shows a prior sale of 4,668 shares on 02/24/2026 generating $17,588.09 in proceeds.
Voyager Therapeutics reported first quarter 2026 results and highlighted progress across its neurology pipeline. Collaboration revenue was $2.6 million, and the company recorded a net loss of $27.9 million, or $0.47 per share, compared with a $31.0 million loss a year earlier.
Research and development expenses fell to $24.6 million, and general and administrative costs declined to $8.3 million, reflecting lower operating spend. Voyager ended the quarter with $171.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
On the pipeline, VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology studies, with clinical entry expected in the second half of 2026. The company also plans mid‑2026 third‑party tau data, first‑in‑human dosing of VY1706, and tau PET imaging efficacy data for antibody VY7523 in late 2026.
Voyager Therapeutics, Inc. reported a net loss of $27.9 million for the three months ended March 31, 2026, slightly improved from $31.0 million a year earlier. Collaboration revenue was $2.6 million, down from $6.5 million, mainly from Neurocrine and Novartis agreements.
Research and development expense fell to $24.6 million from $31.5 million as the company reprioritized its pipeline, including lower spend on discontinued and completed programs while ramping its tau gene therapy candidate VY1706. General and administrative costs declined to $8.3 million.
Cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026, and management currently expects this, along with collaboration reimbursements and interest income, to fund planned operations into 2028. The company had 60.4 million common shares outstanding as of April 30, 2026.